Novel GIP/GLP-1 Yields Uneven Findings in Diabetes Patients With Obesity

(MedPage Today) -- An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed, but tolerability remains a concern. Participants taking 3.6 mg and 6...